Restructuring of domestic drug makers foreseeable

Influenced by a free trade accord between Korea and the United States and a new public health insurance regulation, the so-called positive list system, a number of Korean drug makers are likely to accelerate their restructuring programs through mergers and acquisitions.

Samyang Corporation and Kwandgong Pharm are renewing their M&A bids, as part of efforts to seek the knowledge-intensive ind...